Novartis presents new data at EURETINA 2017 confirming Lucentis efficacy and durability vs aflibercept
Interim results of the head-to-head RIVAL study confirm strong efficacy and comparable durability versus aflibercept in patients with nAMD. Five-year results from the Lucentis LUMINOUS study, the largest ever in retinal disease, demonstrate real-world efficacy and safety across five retinal diseases Novartis, the global leader in ophthalmology, today reported new data confirming Lucentis (ranibizumab) efficacy and durability in patients with nAMD at the 17th EURETINA Congress in Barcelona, Spain (September 7-10, 2017). One-year interim results from the Phase IV head-to-head RIVAL study compared ranibizumab versus aflibercept using a treat-and-extend treatment regimen in patients with neovascular age-related macular degeneration (nAMD). Additionally, five-year results from the LUMINOUS study confirm the real-world efficacy and safety of Lucentis in patients with nAMD, visual impairment due to diabetic macular edema, branch retinal vein occlusion, central retinal vein occlusion and myopic choroidal neovascularization. LUMINOUS is a real-world study assessing the long-term effects of Lucentis in more than 30,000 patients being treated across five different eye diseases in 43 countries across 494 sites, making this the largest-ever study in retinal disease. This data deepens our knowledge of how the product is being used by patients in the real world. "We are delighted by the RIVAL data, which confirms unsurpassed efficacy of Lucentis," said Vas Narasimhan, Global Head, Drug Development and Chief Medical Officer, Novartis.
